PHVS - Pharvaris N.V. News

Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $46

Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and r

Pharvaris Highlights New Deucrictibant Data at EAACI 2026, Says HAE Treatment Data Support On-Demand

Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 recept

Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026

ZUG, Switzerland, June 15, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharma

Pharvaris Announces Annual General Meeting of Shareholders

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharma

Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmac

seekingalpha.com

Pharvaris N.V. (PHVS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Citizens Maintains Market Outperform on Pharvaris, Lowers Price Target to $74

Citizens analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and

Pharvaris Q1 EPS $(0.69) Beats $(0.77) Estimate

Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.69) per share which beat the analyst consen

Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update

Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE

fool.com

Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000

This clinical-stage biotech, focused on rare disease therapies, reported a notable insider sale amid

Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exer

ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a lat

Pharvaris Prices Underwritten Offering Of 3,874,664 Shares At $29.68 Per Share

All shares in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the under

Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares

ZUG, Switzerland, May 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a lat

fool.com

For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next

This biopharma innovator in rare disease therapies reported a notable insider sale amid a year of st

Pharvaris (NASDAQ:PHVS) CEO Berndt Modig Sells 2,292 Shares of Stock

Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) CEO Berndt Modig sold 2,292 shares of the business's

Pharvaris Presents Data Evaluating Safety Margins Of Administration Of Deucrictibant IR Capsule In C

Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring

ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharm

fool.com

Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors.

This clinical-stage biotech focused on rare disease therapies reported a notable insider sale amid a

Tudor Investment Corp ET AL Takes Position in Pharvaris N.V. $PHVS

Tudor Investment Corp ET AL purchased a new stake in Pharvaris N.V. (NASDAQ: PHVS) during the third

Wolfe Research Initiates Coverage On Pharvaris with Outperform Rating, Announces Price Target of $42

Wolfe Research analyst Andy Chen initiates coverage on Pharvaris (NASDAQ:PHVS) with a Outperform

Wedbush Maintains Outperform on Pharvaris, Raises Price Target to $42

Wedbush analyst Laura Chico maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the pr

Pharvaris Moves Closer To New Preventive Treatment For Rare Swelling Disorder

Pharvaris enrolled deucrictibant XR for HAE in CHAPTER 3. Positive results could lend 30% upside to

RBC Capital Maintains Outperform on Pharvaris, Lowers Price Target to $51

RBC Capital analyst Brian Abrahams maintains Pharvaris (NASDAQ:PHVS) with a Outperform and lowers

Earnings Scheduled For April 2, 2026

Pharvaris Q4 EPS $(0.84) Misses $(0.69) Estimate

Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.84) per share which missed the analyst cons

Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

ZUG, Switzerland, April 02, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharm

zacks.com

Does Pharvaris (PHVS) Have the Potential to Rally 59.93% as Wall Street Analysts Expect?

The mean of analysts' price targets for Pharvaris (PHVS) points to a 59.9% upside in the stock. Whil

Pharvaris Announces Publication Of Data From Two Randomized Phase 2 Studies, CHAPTER-1 And RAPIDe-1,

Results from Phase 2 clinical studies, CHAPTER-1 and RAPIDe-1, provide evidence of viability of brad

Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Heredita

ZUG, Switzerland, March 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharm

Pharvaris N.V. (NASDAQ:PHVS) Receives $41.70 Consensus Target Price from Brokerages

Shares of Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) have earned an average recommendation of "

Pharvaris N.V. $PHVS Shares Purchased by General Atlantic L.P.

General Atlantic L.P. raised its stake in Pharvaris N.V. (NASDAQ: PHVS) by 6.6% during the third qua

Pharvaris Publishes Real‑World HAE Study In Clinical Reviews In Allergy & Immunology To Inform On‑De

Data include a concurrent assessment of results collected from PGI and AMRA instruments, insights in

Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks

ZUG, Switzerland, March 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharm

RBC Capital Initiates Coverage On Pharvaris with Outperform Rating, Announces Price Target of $52

RBC Capital analyst Brian Abrahams initiates coverage on Pharvaris (NASDAQ:PHVS) with a Outperfor

HC Wainwright & Co. Reiterates Buy on Pharvaris, Maintains $60 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Pharvaris (NASDAQ:PHVS) with a Buy

Pharvaris Summarized The Presentations For The American Academy Of Allergy, Asthma & Immunology Annu

RAPIDe-3 met the primary and all 11 secondary efficacy endpoints with high statistical significance

Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic

ZUG, Switzerland, March 02, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharm

Oppenheimer Maintains Outperform on Pharvaris, Raises Price Target to $50

Oppenheimer analyst Justin Kim maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the

Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $39

Guggenheim analyst Debjit Chattopadhyay maintains Pharvaris (NASDAQ:PHVS) with a Buy and raises t

Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $41

Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and r

B of A Securities Maintains Neutral on Pharvaris, Raises Price Target to $30

B of A Securities analyst Tazeen Ahmad maintains Pharvaris (NASDAQ:PHVS) with a Neutral and raise

HC Wainwright & Co. Reiterates Buy on Pharvaris, Maintains $60 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Pharvaris (NASDAQ:PHVS) with a Buy

Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows

Pharvaris reports Phase 3 data showing its oral HAE treatment delivers rapid relief, fewer second do

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Pharvaris' RAPIDe-3 Phase 3 Trial Of Deucrictibant For The On-demand Treatment Of Hereditary Angioed

Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly f

Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $37

Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and r

Wedbush Maintains Outperform on Pharvaris, Raises Price Target to $30

Wedbush analyst Laura Chico maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the pr

HC Wainwright & Co. Reiterates Buy on Pharvaris, Maintains $60 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Pharvaris (NASDAQ:PHVS) with a Buy

Pharvaris Q3 EPS $(0.64) Beats $(0.78) Estimate

Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.64) per share which beat the analyst consen